212 related articles for article (PubMed ID: 22376193)
1. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines.
Nacif MS; Arai AE; Lima JA; Bluemke DA
J Cardiovasc Magn Reson; 2012 Feb; 14(1):18. PubMed ID: 22376193
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice.
Meng H; Grosse-Wortmann L
J Cardiovasc Magn Reson; 2012 Aug; 14(1):56. PubMed ID: 22871150
[TBL] [Abstract][Full Text] [Related]
3. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration.
Yang L; Krefting I; Gorovets A; Marzella L; Kaiser J; Boucher R; Rieves D
Radiology; 2012 Oct; 265(1):248-53. PubMed ID: 22923714
[TBL] [Abstract][Full Text] [Related]
4. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?
Tamburrini O; Balducci A
Radiol Med; 2012 Feb; 117(1):1-5. PubMed ID: 22020430
[TBL] [Abstract][Full Text] [Related]
7. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
[No Abstract] [Full Text] [Related]
8. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
Thomsen HS
Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium Retention After Contrast-Enhanced MRI.
Levine D; McDonald RJ; Kressel HY
JAMA; 2018 Nov; 320(18):1853-1854. PubMed ID: 30208489
[No Abstract] [Full Text] [Related]
11. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe.
Leiner T; Kucharczyk W
J Magn Reson Imaging; 2009 Dec; 30(6):1357-63. PubMed ID: 19937935
[TBL] [Abstract][Full Text] [Related]
12. NSF: still relevant.
Thomsen HS
J Magn Reson Imaging; 2014 Jul; 40(1):11-2. PubMed ID: 24990765
[No Abstract] [Full Text] [Related]
13. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
Heverhagen JT; Krombach GA; Gizewski E
Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
[TBL] [Abstract][Full Text] [Related]
14. [Nephrogenic systemic fibrosis (NSF): Effects of stricter guidelines on the use of contrast media containing gadolinium].
Hägele J; Simon M
Radiologe; 2011 Oct; 51(10):831-2. PubMed ID: 21947240
[No Abstract] [Full Text] [Related]
15. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
16. Updates to the ACR Manual on Contrast Media.
Kodzwa R
Radiol Technol; 2017 Nov; 89(2):186-189. PubMed ID: 29298922
[No Abstract] [Full Text] [Related]
17. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
Martin DR
Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
[No Abstract] [Full Text] [Related]
18. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.
Martin DR; Krishnamoorthy SK; Kalb B; Salman KN; Sharma P; Carew JD; Martin PA; Chapman AB; Ray GL; Larsen CP; Pearson TC
J Magn Reson Imaging; 2010 Feb; 31(2):440-6. PubMed ID: 20099361
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis and the role of gadolinium contrast media.
van der Molen AJ
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):339-50. PubMed ID: 18811757
[TBL] [Abstract][Full Text] [Related]
20. The Risk of Nephrogenic Systemic Fibrosis in Group II and III Gadolinium-Based Contrast Agents.
Costa AF
Can Assoc Radiol J; 2020 Nov; 71(4):536. PubMed ID: 32063014
[No Abstract] [Full Text] [Related]
[Next] [New Search]
